Literature DB >> 15353265

Tachykinin-modulated anti-viral responses.

Kenneth L Bost1.   

Abstract

Following viral infection, the expression of substance P and its receptor can contribute significantly to the resulting host response. For gammaherpesvirus infection of mice, the presence of this tachykinin and its receptor contributes to the protective host response. It is likely that this augmentation of the immune response is directed toward the developing T helper type 1 response and cytotoxic T lymphocyte activation. However it has also been shown that the presence of substance P and its receptor may contribute to viral diseases by facilitating viral replication or by contributing to a destructive inflammatory response. Specifically, the presence of substance P can augment replication of HIV in cultured macrophages, which is especially significant since levels of this tachykinin are elevated in patients with this viral disease. Furthermore, rodent models of paramyxovirus infection have demonstrated that the presence of neurokinin receptors and their ligands contributes to the destructive inflammatory response in airways. Taken together, these studies demonstrate a surprising role for substance P and the neurokinin-1 receptor in the host response following these viral infections.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15353265     DOI: 10.2741/1376

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  10 in total

Review 1.  Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation.

Authors:  Steven D Douglas; Susan E Leeman
Journal:  Ann N Y Acad Sci       Date:  2010-11-22       Impact factor: 5.691

Review 2.  Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis.

Authors:  Susmit Suvas
Journal:  J Immunol       Date:  2017-09-01       Impact factor: 5.422

3.  Substance P in the corneal stroma regulates the severity of herpetic stromal keratitis lesions.

Authors:  Brandon S Twardy; Rudragouda Channappanavar; Susmit Suvas
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-04       Impact factor: 4.799

4.  Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation.

Authors:  J-P Lai; W Z Ho; L E Kilpatrick; X Wang; F Tuluc; H M Korchak; S D Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-04       Impact factor: 11.205

5.  Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.

Authors:  Sergei Spitsin; Pablo Tebas; Jeffrey S Barrett; Vasiliki Pappa; Deborah Kim; Deanne Taylor; Dwight L Evans; Steven D Douglas
Journal:  JCI Insight       Date:  2017-10-05

6.  Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.

Authors:  Jeffrey S Barrett; Sergei Spitsin; Ganesh Moorthy; Kyle Barrett; Kate Baker; Andrew Lackner; Florin Tulic; Angela Winters; Dwight L Evans; Steven D Douglas
Journal:  J Transl Med       Date:  2016-05-26       Impact factor: 5.531

7.  Human microglia and astrocytes constitutively express the neurokinin-1 receptor and functionally respond to substance P.

Authors:  Amanda R Burmeister; M Brittany Johnson; Vinita S Chauhan; Megan J Moerdyk-Schauwecker; Ada D Young; Ian D Cooley; Alejandra N Martinez; Geeta Ramesh; Mario T Philipp; Ian Marriott
Journal:  J Neuroinflammation       Date:  2017-12-13       Impact factor: 8.322

8.  Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis.

Authors:  Alejandra N Martinez; Amanda R Burmeister; Geeta Ramesh; Lara Doyle-Meyers; Ian Marriott; Mario T Philipp
Journal:  J Neuroinflammation       Date:  2017-02-15       Impact factor: 8.322

Review 9.  The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS Disorders.

Authors:  M Brittany Johnson; Ada D Young; Ian Marriott
Journal:  Front Cell Neurosci       Date:  2017-01-04       Impact factor: 5.505

10.  Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.

Authors:  Pablo Tebas; Sergei Spitsin; Jeffrey S Barrett; Florin Tuluc; Okan Elci; James J Korelitz; Wayne Wagner; Angela Winters; Deborah Kim; Renae Catalano; Dwight L Evans; Steven D Douglas
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.